Xtl Biopharmaceuticals Ltd
XTLB Nasdaq· Pharmaceutical Preparations
Last close · Oct 30, 2026
$1.61
KIRA · Stoqly’s AI analyst, in plain words
- Xtl Biopharmaceuticals Ltd had only $0.0M of revenue in fiscal 2025: it is still developing what it sells. It spent $0.0M on research and development, 2% of its operating costs.
- Its operating margin was −24,114.3%, down 23,942.4 pts: of every 100 in sales, about −24,114 is left after running the business.
- Xtl Biopharmaceuticals Ltd lost $7.0M in fiscal 2025. With no meaningful sales yet, it pays for its work from the cash it holds.
- Operating cash flow was −$1.0M in fiscal 2025. At that burn of $1.0M a year, its $0.1M of cash and short-term investments would last about 0.1 years.
Market cap
$1.4B
P/E
—
Revenue
$0.0M
Net income
−$7.0M
Free cash flow
—
Operating margin
−24,114.3%
Xtl Biopharmaceuticals Ltd in 30 seconds · fiscal 2025
Are shareholders being diluted?
+33.2%
A lot. The share count rose 33.2% last year, so each share owns noticeably less.
Does it make a profit?
$0.0M R&D
Not yet: it has no meaningful sales. It spent $0.0M on research and development, 2% of its operating costs.
How long would its cash last?
0.1 yrs
Not long. It burns $1.0M a year and holds $0.1M, under a year at that pace, so it may need new money soon.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Xtl Biopharmaceuticals Ltd does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Jun 30, 2026
- Legal name
- XTL BIOPHARMACEUTICALS LTD
- CIK
- 0001023549
Xtl Biopharmaceuticals Ltd · XTLB · stoqly.net
Results and finances
The last 5 fiscal years. Amounts in USD. Compiled by stoqly.net.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | — | — | $0.5M | $0.0M |
| Revenue growth | — | — | — | — | −98.4% |
| Net interest income | — | — | — | — | $0.0M |
| Gross margin | — | — | — | 0.7% | — |
| Operating margin | — | — | — | −171.8% | −24,114.3% |
| Net income | $0.4M | −$1.3M | −$1.8M | −$1.0M | −$7.0M |
| Net margin | — | — | — | −227.7% | −99,557.1% |
| Diluted EPS | $0.00 | −$0.00 | −$0.00 | −$0.00 | −$0.01 |
| Cash | |||||
| Cash from operations | −$1.0M | −$0.9M | −$0.7M | −$1.6M | −$1.0M |
| Capital expenditure | — | — | — | $0.1M | — |
| Free cash flow | — | — | — | −$1.7M | — |
| FCF margin | — | — | — | −370.7% | — |
| Share count change | 19.7% | −11.5% | −0.0% | 23.5% | 33.2% |
| Debt and strength | |||||
| Cash and short-term investments | $3.0M | $2.1M | $1.4M | $0.4M | $0.1M |
| Debt incl. finance leases | — | — | — | $0.1M | — |
| Loans, net | — | — | — | $1.3M | $0.3M |
| Shareholders' equity | $5.3M | $4.0M | $2.2M | $5.4M | −$0.3M |
| Current ratio | — | — | 9.9x | 0.6x | — |
| Interest coverage | −49.1x | −0.6x | −0.7x | −27.7x | −241.1x |
| Returns and quality | |||||
| Return on capital | — | — | — | −14.9% | — |
| Return on equity | 9.7% | −28.9% | −57.3% | −26.8% | −269.0% |
| Return on tangible equity | 8.8% | −37.2% | −96.8% | — | — |
| Altman Z'' | — | — | −198.5 | −60.1 | — |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Xtl Biopharmaceuticals Ltd · XTLB · stoqly.net
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.61 a share, the company is worth $1.4B.
Compiled and analysed by stoqly.net from SEC EDGAR XBRL filings (CIK 0001023549). Latest version: stoqly.net/companies/xtlb. Data updated November 1, 2026. For information only — not investment advice. Check the original filings before relying on any figure.